NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma

NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma

Descartes-25 in Relapsed/Refractory Multiple Myeloma

This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.

Sponsor

Cartesian Therapeutics

---

ClinicalTrials.gov Identifier: NCT05113342

Official Title: Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma

First Posted: November 9, 2021

Click here to see details on ClinicalTrials.gov

---

Cartesian Therapeutics

Drug: Descartes-25

---

Locations:

United States, Maryland

Center for Cancer and Blood Disorders

Bethesda, Maryland, United States, 20817

United States, Wisconsin

Medical College of Wisconsin

Madison, Wisconsin, United States, 53226